Prevention and Early Treatment of Diabetic Renal Disease

  • Carl Erik Mogensen


Throughout the course of diabetes, good metabolic control is of major importance in the prevention of renal disease (1). Later in the diabetic course, several factors appear to affect disease progression, and blood pressure elevation seems the most important factor, readily modifiable. Incipient renal disease in diabetes, detected by the occurrence of microalbuminuria, is frequently characterized by elevated and increasing blood pressure. The increase, however, is most often subtle and may only be detectable by careful monitoring, e.g., 24-hour ambulatory recordings (2). Elevation of blood pressure is found in both types of diabetes, but there seem to be several etiological as well as temporal distinctions between insulin-dependent diabetes mellitus (IDDM) and noninsulin-dependent diabetes mellitus (NIDDM), and some of these variations are clearly explained by the different etiology and nature of the diabetic state (3). In NIDDM patients, higher age, increased body weight, and insulin resistance and related hyperinsulinemia are important factors. Though hypertension secondary to renal impairment is also frequently seen in NIDDM patients, the renal genesis of hypertension is much more predominant in the relatively younger IDDM patients (3). Dietary protein may also be an important modulating factor, but further studies are needed, since this is an area of controversy (4). These three factors—metabolic control, blood pressure elevation, and dietary proteins—and their modification by treatment will be the main focus in this chapter.


Diabetic Nephropathy Blood Pressure Elevation Antihypertensive Treatment Fall Rate NIDDM Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parving H-H, Rossing P, Hommel E, Smidt UM: Angiotensin converting enzyme inhibition in diabetic nephropathy: ten years experience. Am J Kidney Dis, 26: 99–107, 1995.PubMedCrossRefGoogle Scholar
  2. 2.
    Hansen KW, Poulsen PL, Mogensen CE: Ambulatory blood pressure and abnormal albuminuria in type 1 diabetic patients. Kidney Int 45 (Suppl 45): S134 - S140, 1994.Google Scholar
  3. 3.
    Mogensen CE, Ÿ sterby R, Hansen KW, Damsgaard EM: Blood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes. Diabetes Care 15: 1192–1204, 1992.PubMedCrossRefGoogle Scholar
  4. 4.
    Mau Pedersen M, Mogensen CE, Schonau Jorgensen F, Moller B, Lykke G, Pedersen O: Renal effects from limitation of high dietary protein in normoalbuminuric insulin-dependent diabetic patients. Kidney Int 36 (Suppl 27): S115 - S121, 1989.Google Scholar
  5. 5.
    Parving H-H, Rossing P: The use of antihypertensive agents in prevention and treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 3: 292–300, 1994.PubMedCrossRefGoogle Scholar
  6. 6.
    Viberti GC, Messent J: Introduction: hypertension and diabetes. Critical combination for micro-and macrovascular disease. Diabetes Care 14 (Suppl 4): 4–7, 1991.PubMedGoogle Scholar
  7. 7.
    Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving H-H, Steffes MW, Striker GE: Screening and management of microalbuminuria in patients with diabetes mellitus—recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney 25: 107–112, 1995.CrossRefGoogle Scholar
  8. 8.
    Mogensen CE: Definition of diabetic renal disease in insulin-dependent diabetes mellitus based on renal function tests. In: CE Mogensen, ed, The Kidney and Hypertension in Diabetes Mellitus, 3rd ed. Kluwer Academic Publishers, Boston, Dordrecht, London, pp 11–22, 1997.Google Scholar
  9. 9.
    Parving H-H, Kastrup J, Smidt UM, Andersen AR, FeldtRasmussen B, Christiansen JS: Impaired autoregulation of glomerular filtration rate in type 1 (insulin-dependent) diabetics with diabetic nephropathy. Diabetologia 27: 547–552, 1984.PubMedCrossRefGoogle Scholar
  10. 10.
    Ferrannini E• The metabolic syndrome. In: CE Mogensen, ed, Target Organ Damage in the Mature Hypertensive. Science Press, London, pp 2.31–2.49, 1993.Google Scholar
  11. 11.
    Pettitt DJ, Knowler WC: Nelson R6 Familial factors in diabetic nephropathy. In: CE Mogensen, ed, The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publishers, Boston, Dordrecht, London, pp 35–43, 1997.Google Scholar
  12. 12.
    Powrie JK, Watts GF, Ingham JN, Taub NA, Talmud PJ, Shaw KM: Role of glycaemic control in development of microalbuminuria in patients with insulin dependent diabetes. Br Med J 309: 1608–1612, 1994.CrossRefGoogle Scholar
  13. 13.
    Mogensen CE: Angiotensin converting enzyme inhibitors and diabetic nephropathy (editorial). Br Med J 304: 227–228, 1992.CrossRefGoogle Scholar
  14. 14.
    Lewis EJ, Hunsicker LG, Bain RP, Rhode RD: The effect of angiotensin-converting-enzyme inhibition on nephropathy. N Engl J Med 329: 1456–1462, 1993.PubMedCrossRefGoogle Scholar
  15. 15.
    Mogensen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 285: 685688, 1982.Google Scholar
  16. 16.
    Christensen CK, Mogensen CE: Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 7 (Suppl I):II-109-II-113, 1985.Google Scholar
  17. 17.
    The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977986, 1993.Google Scholar
  18. 18.
    Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive inulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulindependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103–117, 1995.PubMedCrossRefGoogle Scholar
  19. 19.
    Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T: Improved survival in patients with diabetic nephropathy. Diabetologia 32: 884–886, 1989.PubMedCrossRefGoogle Scholar
  20. 20.
    osterby R, Bangstad H-J, Nyberg G, Mauer SM, Steffes MW: A quantitative ultrastructural study of juxtaglomerular arterioles in insulin-dependent diabetic patients with micro-albuminuria and in controls. Eur J Clin Invest 24 (Suppl 2): A50, 1994.Google Scholar
  21. 21.
    Viberti GC, Keen H, Wiseman MJ: Raised arterial pressure in parents of proteinuric insulin-dependent diabetics. Br Med J 295: 515–517, 1987.CrossRefGoogle Scholar
  22. 22.
    Norgaard K, Feldt-Rasmussen B, Borch-Johnsen K, Sælan H, Deckert T: Prevalence of hypertension in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33: 407410, 1990.Google Scholar
  23. 23.
    Damsgaard EM, Mogensen CE: Microalbuminuria in elderly hyperglycaemic patients and controls. Diabetic Med 3: 430435, 1986.Google Scholar
  24. 24.
    United Kingdom Prospective Diabetes Study: A multicenter study. III. Prevalence of hypertension and hypotensive therapy in patients with newly diagnosed diabetes. Hypertension 7 (Suppl II):II-8-II-13, 1985.Google Scholar
  25. 25.
    Olivarius N de F, Andreasen AH, Keiding N, Mogensen CE: Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study “Diabetes care in General Practice,” Denmark. Diabetologia 36: 1007–1016, 1993.CrossRefGoogle Scholar
  26. 26.
    Schmitz A: The kidney in non-insulin-dependent diabetes. Studies on glomerular structure and function and the relationship between microalbuminuria and mortality. Acta Diabetologica 29: 47–69, 1992.CrossRefGoogle Scholar
  27. 27.
    Feldt-Rasmussen B, Mathiesen ER, Deckert T: Effect of two years of strict metabolic control on the progression of incipient nephropathy in insulin-dependent diabetes. Lancet II: 1300–1304, 1986.PubMedCrossRefGoogle Scholar
  28. 28.
    Parving H-H, Smidt UM, Andersen AR, Svendsen PAa: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet i: 1175–1179, 1983.Google Scholar
  29. 29.
    Mogensen CE: Hyperfiltration, hypertension, and diabetic nephropathy in IDDM patients. Diabetes Nutr Metab 2: 227244, 1989.Google Scholar
  30. 30.
    Nielsen S, Schmitz A, Poulsen PL, Hansen KW, Mogensen CE: Changes in 24 hour ambulatory blood pressure related to albuminuria in NIDDM patients without proteinuria (abstract). Diabetologia 37: A193, 1994.Google Scholar
  31. 31.
    Schmitz A, Væth M, Mogensen CE: Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 37: 1251–1258, 1994.PubMedCrossRefGoogle Scholar
  32. 32.
    Borch-Johnsen K: Incidence of nephropathy in insulin-dependent diabetes mellitus as related to mortality and cost-benefic of early intervention. In: CE Mogensen, ed, The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publishers, Boston, Dordrecht, London, pp 107–115, 1997.Google Scholar
  33. 33.
    Mau Pedersen M, Christensen CK, Mogensen CE: Longterm (18 year) prognosis for normo-and microalbuminuric type 1 (insulin-dependent) diabetic patients (abstract). Diabetologia 35: A60, 1992.CrossRefGoogle Scholar
  34. 34.
    Messent JWC, Elliott TG, Hill RD, Jarrett RJ, Keen H, Viberti GC: Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 41: 836–839, 1992.PubMedCrossRefGoogle Scholar
  35. 35.
    Mogensen CE, Hansen KW, Nielsen S, Mau Pedersen M, Rehling M, Schmitz A: Monitoring diabetic nephropathy: glomerular filtration rate and abnormal albuminuria in diabetic renal disease-reproducibility, progression, and efficacy of antihypertensive intervention. Am J Kidney Dis 22: 174–187, 1993.PubMedGoogle Scholar
  36. 36.
    Mogensen CE, Mau Pedersen M, Hansen KW, Christensen CK: Micro-albuminuria and the organ-damage concept in antihypertensive therapy for patients with insulin-dependent diabetes mellitus. J Hypertens 10 (Suppl 1): S43 - S51, 1992.CrossRefGoogle Scholar
  37. 37.
    Mogensen CE, Damsgaard EM, Froland A, Hansen KW, Nielsen S, Mau Pedersen M, Schmitz A, Thuesen L, Clsterby R: Reduced glomerular filtration rate and cardiovascular damage in diabetes: a key role for abnormal albuminuria. Acta Diabetologica 29: 201–213, 1992.CrossRefGoogle Scholar
  38. 38.
    Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T: Effect of improved metabolic control loss of kidney function in Type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 34: 164–170, 1991.PubMedCrossRefGoogle Scholar
  39. 39.
    Mogensen CE: Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 36: 383–388, 1976.PubMedCrossRefGoogle Scholar
  40. 40.
    Mathiesen ER, Hommel E, Giese J, Parving H-H: Efficacy of captopril in postponing nephropathy in normotensive insulin-dependent diabetic patients with microalbuminuria. Br Med J 303: 81–87, 1991.CrossRefGoogle Scholar
  41. 41.
    Norgaard K, Rasmussen E, Jensen T, Giese J, FeldtRasmussen B: Essential hypertension and type 1 diabetes. Am J Hypertens 6: 830–836, 1993.PubMedGoogle Scholar
  42. 42.
    Mogensen CE, Vigstrup J, Ehlers N: Microalbuminuria predicts proliferative diabetic retinopathy. Lancet ii: 1512–1513, 1985.Google Scholar
  43. 43.
    Klein R, Moss SE, Klein BEK: Gross proteinuria predicts the incidence of proliferative diabetic retinopathy (abstract). Diabetes 41 (Suppl 1):no. 129.Google Scholar
  44. 44.
    Norgaard K, Feldt-Rasmussen B, Deckert T: Is hypertension a major independent risk factor for retinopathy in Type 1 diabetes? Diabetic Med 8: 334–337, 1991.PubMedCrossRefGoogle Scholar
  45. 45.
    Stephenson J, the Eurodiab IDDM Complications Study Group: Blood pressure and urinary albumin excretion in IDDM. Diabetes 42 (Suppl 1): 29A, 1993.Google Scholar
  46. 46.
    Knowler WC, Bennett PH, Ballintine EJ: Increased incidence of retinopathy in diabetics with elevated blood pressure. A six-year follow-up study in Pima Indians. N Engl J Med 302: 645–650, 1980.PubMedCrossRefGoogle Scholar
  47. 47.
    Casale PN, Devereux RB, Milner M: Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 105: 173–178, 1986.PubMedCrossRefGoogle Scholar
  48. 48.
    Thuesen L, Christiansen JS, Mogensen CE, Henningsen P: Echocardiographic-determined left ventricular wall characteristics in insulin dependent diabetic patients. Acta Med Scand 224: 343–348, 1988.PubMedCrossRefGoogle Scholar
  49. 49.
    Poulsen PL, Hansen KW, Mogensen CE: Ambulatory blood pressure in the transition from normo-to microalbuminuria. A longitudinal study in IDDM patients. Diabetes 43: 1248 1253, 1994.Google Scholar
  50. 50.
    Bangstad H-J, Osterby R, Dahl-Jorgensen K, Berg KJ, Hartmann A, Hanssen KF: Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 37: 483–490, 1994.PubMedCrossRefGoogle Scholar
  51. 51.
    Feldt-Rasmussen B, Norgaard K, Jensen T, Deckert T: Microalbuminuria, clinical nephropathy and hypertension in diabetes. J Hum Hypertens 5: 255–263, 1991.PubMedGoogle Scholar
  52. 52.
    Weidmann P, Ferrari P: Central role of sodium in hypertension in diabetic subjects. Diabetes Care 14: 220–232, 1991.PubMedCrossRefGoogle Scholar
  53. 53.
    Thuesen L, Christiansen JS, Mogensen CE, Henningsen P: Cardiac hyperfunction in insulin-dependent diabetic patients developing microvascular complications. Diabetes 37: 85 1856, 1988.Google Scholar
  54. 54.
    Sandeman DD, Shore AC, Tooke JE: Relation of skin capillary pressure in patients with insulin-dependent diabetes mellitus to complications and metabolic control. N Engl J Med 327: 760–764, 1992.PubMedCrossRefGoogle Scholar
  55. 55.
    Gans ROB, Bilo HJG, Nauta JJP, Heine RJ, Donker AJM: Acute hyperinsulinemia induces sodium retention and a blood pressure decline in diabetes mellitus. Hypertension 20: 199–209, 1992.PubMedCrossRefGoogle Scholar
  56. 56.
    Daly PA, Landsberg L: Hypertension in obesity and NIDDM. Role of insulin and sympathetic nervous system. Diabetes Care 14: 240–248, 1991.PubMedCrossRefGoogle Scholar
  57. 57.
    Vora JP, Anderson S, Brenner: Pathogenesis of diabetic glomerulopathy: the role of glomerular hemodynamic factors. In: CE Mogensen, ed, The Kidney and Hypertension in Diabetes Mellitus. Kluwer Academic Publishers, Boston, Dordrecht, London, pp 253–261, 1997.Google Scholar
  58. 58.
    Malmberg K, Herlitz J, Hjalmarson A, Rydén L: Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction: retrospective data from two large studies. Eur Heart J 10: 423–428, 1989.PubMedGoogle Scholar
  59. 59.
    Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr: Diabetic patients and ß-blockers after acute myocardial infarction. Eur Heart J 11: 43–50, 1990.PubMedGoogle Scholar
  60. 60.
    Carlsen J, Kober C, Torp-Pedersen C, Johansen P: Relation between dose of bendrofuazide antihypertensive effect and adverse biochemical effect. Br Med J 300: 975–978, 1990.CrossRefGoogle Scholar
  61. 61.
    Torlone E, Britta M, Rambotti AM, Perriello G, Santeusanio F, Brunetti P, Bolli GB: Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes. Diabetes Care 16: 1347–1355, 1993.PubMedCrossRefGoogle Scholar
  62. 62.
    Rossing P, Hommel E, Smidt UM, Parving H-H: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37: 511–516, 1994.PubMedCrossRefGoogle Scholar
  63. 63.
    Mau Pedersen M, Schmitz A, Pedersen EB, Danielsen H, Christiansen JS: Acute and long-term renal effects of angiotensin converting enzyme inhibition in normotensive, normoalbuminuric insulin-dependent diabetics. Diabetic Med 5: 562–569, 1988.PubMedCrossRefGoogle Scholar
  64. 64.
    Marre M, Chatellier G, Leblanc H, Guyenne T-T, Ménard J, Passa PH: Prevention of diabetic nephropathy with Enalapril in normotensive diabetics with microalbuminuria. Br Med J 297: 1092–1095, 1988.CrossRefGoogle Scholar
  65. 65.
    Rudberg S, Aperia A, Freyschuss U, Persson B: Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 33: 470–476, 1990.PubMedCrossRefGoogle Scholar
  66. 66.
    Cook JJ, Daneman D, Spino M, Sochett E, Perlman K, Balfe JW: Angiotensin converting enzyme inhibitor therapy to decrease microalbuminuria in normotensive children with insulin-dependent diabetes mellitus. J Pediatr 117: 39–45, 1990.PubMedCrossRefGoogle Scholar
  67. 67.
    Melbourne Diabetic Nephropathy Study Group: Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Be Med J 302: 210–216, 1991.CrossRefGoogle Scholar
  68. 68.
    Marre M, Hallab M, Billiard A, Le Jeune JJ, Bled F, Girault A, Fressinaud PH: Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes. J Cardiovasc Pharmacol 18 (Suppl 2): S165 - S168, 1991.PubMedGoogle Scholar
  69. 69.
    The EUCLID study group. A rande mised placebo controlled trial of lisinopril on urinary albumin excretion rate in normotensive insulio dependent diabetes (IDDM) patients with normalbuminuria or microalbuminuria, Lancet 1997 in press.Google Scholar
  70. 70.
    Viberti G, Mogensen CE, Groop LC, Pauls JF, for the European Microalbuminuria Captopril Study Group: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271: 275–279, 1994.PubMedCrossRefGoogle Scholar
  71. 71.
    Mogensen CE, Hansen KW, Mau Pedersen M, Christensen CK: Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 14 (Suppl 4): 13–26, 1991.PubMedGoogle Scholar
  72. 72.
    Mogensen CE, Keane WF, Bennett PH, Jerums G, Parvivy HH, Passa P, Stelles MW, Striker GE, Vilerti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346: 1080–1084, 1995.PubMedCrossRefGoogle Scholar
  73. 73.
    Chan JCN, Cockram CS, Nicholls MG, Cheung CK, Swaminathan R: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. Br Med J 305:981–985Google Scholar
  74. 74.
    Lacourcière Y, Nadeau A, Poirier L, Tancrède G: Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 21: 786–794, 1993.PubMedCrossRefGoogle Scholar
  75. 75.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577–581, 1993.PubMedCrossRefGoogle Scholar
  76. 76.
    Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, Bolton WK: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int 45 (Suppl 45): S150 - S155, 1994.Google Scholar
  77. 77.
    Nielsen S, Schmitz A, Rehling M, Mogensen CE: Systolic blood pressure relates to the rate of decline of glomerular filtration rate in Type 2 diabetes. Diabetes Care 16: 1427 1432, 1993.Google Scholar
  78. 78.
    Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PAa: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 294: 1443–1447, 1987.CrossRefGoogle Scholar
  79. 79.
    Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. B Med J 304: 339–343, 1992.CrossRefGoogle Scholar
  80. 80.
    Baba T, Murabayashi S, Tomiyama T, Takebe K: Uncontrolled hypertension is associated with rapid progression of nephropathy in type 2 diabetic patients with proteinuria and preserved renal function. Tohoku J Exp Med 161: 741–748, 1990.CrossRefGoogle Scholar
  81. 81.
    Gall M-A, Nielsen FS, Smidt UM, Parving H-H: The course of kidney function in Type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 36: 1071–1078, 1993.PubMedCrossRefGoogle Scholar
  82. 82.
    Dullaart RPF, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ: Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care 16: 483–492, 1993.PubMedCrossRefGoogle Scholar
  83. 83.
    Walker JD: Non-glycaemic intervention in diabetic nephropathy: the role of dietary protein intake. In: CE Mogensen, ed, The Kidney and Hypertension in Diabetes Mellitus, 3rd ed. Kluwer Academic Publishers, Boston, Dordrecht, London, pp 405–414, 1997.Google Scholar
  84. 84.
    Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR: Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 324: 78–84, 1991.PubMedCrossRefGoogle Scholar
  85. 85.
    Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G, for the Modification of Diet in Renal Disease Study Group: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330: 877–884, 1994.PubMedCrossRefGoogle Scholar
  86. 86.
    Nyberg G, Nordén G, Attman P-O, Aurell M, Uddebom G, Lenner RA, Isaksson B: Diabetic nephropathy: is dietary protein harmful? J Diabetic Complications 1: 37–40, 1987.CrossRefGoogle Scholar
  87. 87.
    Kofoed-Enevoldsen A: The Steno hypothesis and glomerular basement membrane biochemistry in diabetic nephropathy. In: CE Mogensen, ed, The Kidney and Hypertension in Diabetes Mellitus, 2nd ed. Kluwer Academic Publishers, Boston, Dordrecht, London, pp 235–243, 1997.Google Scholar
  88. 88.
    Cohen MP: General aspects of aldose reductase inhibition. In: CE Mogensen, E Standl, eds, Pharmacology of Diabetes. Present Practice and Future Perspectives. Walter de Gruyter, Berlin, New York, pp 181–191, 1991.Google Scholar
  89. 89.
    Giardino I, Brownlee M: Glycosylatin inhibition. In: CE Mogensen, E Standl, eds, Pharmacology of Diabetes. Present Practice and Future Perspectives. Walter de Gruyter, Berlin, New York, pp 211–220, 1991.Google Scholar
  90. 90.
    Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH: Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 340: 319–323, 1992.PubMedCrossRefGoogle Scholar
  91. 91.
    Stehouwer CDA, Stroes ESG, Hackeng WHL, Mulder PGH, den Ottolander GJH: Von Willebrand factor and development of diabetic nephropathy in IDDM. Diabetes 40: 97 1976, 1991.Google Scholar
  92. 92.
    Franken AAM, Derkx FHM, Man in’t Veld AJ, Hop WCJ, van Rens GH, Peperkamp E, de Jong PTVM, Schalekamp MADH: High plasma prorenin in diabetes mellitus and its correlation with some complications. J Clin Endocrinol Metab 71: 1008–1015, 1990.PubMedCrossRefGoogle Scholar
  93. 93.
    Feldt-Rasmussen B: Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 29: 282–286, 1986.PubMedCrossRefGoogle Scholar
  94. 94.
    Gilbert RE, Tsalamandris C, Bach LA, Panagiotopoulos S, O’Brien RC, Allen TJ, Goodall I, Young V, Seeman E, Murray RML, Cooper ME, Jerums G: Long-term glycemic control and the rate of progression of early diabetic kidney disease. Kidney Int 44: 855–859, 1993.PubMedCrossRefGoogle Scholar
  95. 95.
    Mogensen CE: Renoprotective role of ACE inhibitors in diabetic nephropathy. Br Heart J 72 (Suppl): 38–45, 1994.CrossRefGoogle Scholar
  96. 96.
    Weidmann P, Boehlen LM, de Courten M: Effects of different antihypertensive drugs on human diabetic proteinuria. Nephrol Dial Transplant 8: 582–584, 1993.PubMedGoogle Scholar
  97. 97.
    M, Böhlen L, de Courten Weidman P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. In: CE Mogensen, ed, The Kidney and Hypertension in Diabetes Mellitus, 3nd ed. Kluwer Academic Publishers, Boston, Dordrecht, London, pp 361–374.Google Scholar
  98. 98.
    Parving H-H, Andersen AR, Schmidt UM, Christiansen JS, Oxenboll B, Svendsen PA: Diabetic nephropathy and arterial hypertension-the effect of antihypertensive treatment. Diabetes 32 (Suppl 2): 83–87, 1983.PubMedGoogle Scholar
  99. 99.
    Nyberg G, Blohmé G: Nordén G: Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 30: 82–86, 1987.PubMedGoogle Scholar
  100. 100.
    Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J 293: 471–474, 1986.CrossRefGoogle Scholar
  101. 101.
    Bauer JH, Reams GP, Hewett J, Klachko D, Lau A, Messina C, Knaus V: A randomized, doubleblind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 20: 443–457, 1992.PubMedGoogle Scholar
  102. 102.
    Elving LD, Wetzels JFM, van Lier HJJ, de Nobel E, Berden JHM: Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study. Diabetologia 37: 604–609, 1994.PubMedCrossRefGoogle Scholar
  103. 103.
    Parving H-H, Rossing R, Hommel E, Smidt UM: Renal protective effects of Captopril and Metoprolol in diabetic nephropathy (abstract). J Am Soc Nephrol 3: 337, 1992.Google Scholar
  104. 104.
    Mogensen CE: Systemic blood pressure and glomerular leakage with particular reference to diabetes and hypertension. J Intern Med 235: 297–316, 1994.PubMedCrossRefGoogle Scholar
  105. 105.
    Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard E, Eiskjr H, Froland A, Hansen KW, Nielsen S, Mau Pedersen M: Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 18: 572–581, 1995.PubMedGoogle Scholar
  106. 106.
    Mogensen CE: Management of early nephropathy in diabetic patients. With emphasis on microalbumin-uria. Annu Rev Med 46: 79–94, 1995.PubMedCrossRefGoogle Scholar
  107. 107.
    Mogensen CE: Diabetic renal disease: the quest for normotension-and beyond. Diabetic Med 12:756–769, 1995.Google Scholar
  108. 108.
    Mogensen CE, ed: The Kidney and Hypertension in Diabetes Mellitus,3rd ed. Kluwer Academic Publishers, Boston, Dordrecht, London, 1,997.Google Scholar
  109. 109.
    Alzaid AA: Microalbuminuria in patients with NIDDM: An overview. Diabetes Care 19: 79–89, 1996.PubMedCrossRefGoogle Scholar
  110. 110.
    Gilbert RE, Cooper ME, McNally PG, O’Brien RC, Taft J, Jerums G: Microalbuminuria: Prognostic and therapeutic implications in diabetes mellitus. Diabetic Med 11: 636–645, 1994.PubMedCrossRefGoogle Scholar
  111. 111.
    DeFronzo RA: Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 3: 510–564, 1995.Google Scholar
  112. 112.
    Breyer JA: Medical management of nephropathy in type I diabetes mellitus: Current recommendations. J Am Soc Nephrol 6: 1523–1529, 1995.PubMedGoogle Scholar
  113. 113.
    Gosling P: Microalbuminuria: a marker of systemic disease. Br J Hosp Med 54: 285–290, 1995.PubMedGoogle Scholar
  114. 114.
    Raskin GS, Tamborlane WV: Molecular and physiological aspects of nephropathy in type I (insulin-dependent) diabetes mellitus. J Diabetes and Its Complications 10: 31–37, 1996.CrossRefGoogle Scholar
  115. 115.
    Clark CM, Lee DA: Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 332: 1210–1217, 1995.PubMedCrossRefGoogle Scholar
  116. 116.
    Mogensen CE: »Management of the diabetic patient with elevated blood pressure or renal disease. Early screening and treatment programs: albuminuria and blood pressure.« In Hypertension: Pathology, Diagnosis & Management. 2nd ed, J.H. Laragh, B.M. Brenner, eds. New York: Raven Press Ltd., 1995; pp 2335–2365.Google Scholar
  117. 117.
    Leese GP, Vora JP: The management of hypertension in diabetes: with special reference to diabetic kidney disease. Diabetic Med 13: 401–410, 1996.PubMedCrossRefGoogle Scholar
  118. 118.
    Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell S-E, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC 13 inhibitor. Science 272: 728731, 1996.Google Scholar
  119. 119.
    Drickamer K: Breaking the curse of the AGEs. Nature 382: 211–212, 1996.PubMedCrossRefGoogle Scholar
  120. 120.
    Vasan S, Zhang X, Zhang X, Kapurniotu A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P: An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. Nature 382: 275–278, 1996.PubMedCrossRefGoogle Scholar
  121. 121.
    Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H: Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci USA 93: 3902–3907, 1996.PubMedCrossRefGoogle Scholar
  122. 122.
    Friedman EA: Will pimagidine improve survival of diabetics on dialysis? Nephrol Dial Transplant 11: 1524–1527, 1996.PubMedCrossRefGoogle Scholar
  123. 123.
    Bakris GL: Combination therapy for hypertension and renal disease in diabetics as compency to non-diahetics. In: CE Mogensin ed, The kidney and hypertension in diabetic mellibus 3rd Kluwer Acodemic Publishers, Boston Dordrecht London, pp 561–568, 1997.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Carl Erik Mogensen
    • 1
  1. 1.Medical Department M (Diabetes and Endocrinology), KommunehospitaletKommunehospitalet, University Hospital in AarhusAarhus CDenmark

Personalised recommendations